Wang Y, Lian B, Cui CL. Long-term control of melanoma brain metastases with co-occurring intracranial infection and involuntary drug reduction during COVID-19 pandemic: A case report. World J Clin Cases 2021; 9(10): 2373-2379 [PMID: 33869616 DOI: 10.12998/wjcc.v9.i10.2373]
Corresponding Author of This Article
Chuan-Liang Cui, MD, Chief Physician, Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Beijing 100142, China. 1008ccl@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Apr 6, 2021 (publication date) through Oct 25, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Wang Y, Lian B, Cui CL. Long-term control of melanoma brain metastases with co-occurring intracranial infection and involuntary drug reduction during COVID-19 pandemic: A case report. World J Clin Cases 2021; 9(10): 2373-2379 [PMID: 33869616 DOI: 10.12998/wjcc.v9.i10.2373]
World J Clin Cases. Apr 6, 2021; 9(10): 2373-2379 Published online Apr 6, 2021. doi: 10.12998/wjcc.v9.i10.2373
Long-term control of melanoma brain metastases with co-occurring intracranial infection and involuntary drug reduction during COVID-19 pandemic: A case report
Yang Wang, Bin Lian, Chuan-Liang Cui
Yang Wang, Bin Lian, Chuan-Liang Cui, Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China
Author contributions: Wang Y reviewed the literature and contributed to writing the article; Lian B was the patient’s physician and contributed to extracting the data; Cui CL contributed to revising and editing the article; all authors have read and approved the final manuscript.
Supported byBeijing Municipal Administration of Hospitals’ Youth Programme, No. QML20181101; and Beijing Municipal Administration of Hospitals Incubating Program, No. PX2017042.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: No conflicts of interest are declared.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chuan-Liang Cui, MD, Chief Physician, Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Beijing 100142, China. 1008ccl@163.com
Received: November 24, 2020 Peer-review started: November 24, 2020 First decision: December 21, 2020 Revised: December 27, 2020 Accepted: January 27, 2021 Article in press: January 27, 2021 Published online: April 6, 2021 Processing time: 126 Days and 0.2 Hours
Abstract
BACKGROUND
Melanoma brain metastasis is a common cause of death in melanoma patients and is associated with a poor prognosis. There are relatively few reports on intracranial infections after brain metastasis resection.
CASE SUMMARY
Here we report a case of melanoma brain metastases in a patient harboring a BRAF V600E mutation, who experienced intracranial tumor progression despite previous combined treatment with a programmed death (PD)-1 inhibitor, axitinib, and vemurafenib. She repeatedly underwent local therapy, including stereotactic radiosurgery and intracranial surgery, and developed central nervous system infection. Treatment with vemurafenib combined with cobimetinib resulted in an intracranial progression-free survival of 10 mo. During the coronavirus disease 2019 (COVID-19) pandemic, the patient did not visit the hospital for regular vemurafenib treatment, and experienced intracranial progression after involuntary drug reduction for 1 mo. The patient subsequently received various systemic treatments including vemurafenib, PD-1 inhibitor, and chemotherapy, with an overall survival of 29 mo as of September 2020.
CONCLUSION
We report the first case of melanoma brain metastases with co-occurring intracranial infection and unintended drug reduction during the COVID-19 outbreak. Long-term control of the intracranial lesions was achieved with systemic and local therapies.
Core Tip: We report a melanoma patient with brain metastases who had long-term control of intracranial lesions with the combination of local therapy and BRAF/MEK inhibitor. During the treatment course, the patient experienced intracranial infection and unwanted drug reduction during the coronavirus disease 2019 outbreak.
